Where Strategy, Partnerships, and Growth Meet
Gain the insights you need to source, structure, and close high-value deals. Learn from experts in licensing, M&A, venture capital, and strategic alliances to elevate your BD approach.
Fierce Biotech Week 2026
May 12-14th
Extended Deadline!
Super Early Bird Savings: Save $1,300 through February 27th
Who Will You Be Joining?
Here's a small sample of attendees:
Ex-SVP, Global Head of Portfolio Strategy, Biocon Biologics
VP Corporate Strategic Partnerships, Lindy Biosciences
Senior Director, e-Therapeutics PLC
External Alliances Management Lead, Takeda Pharmcaeuticals (formerly)
(former) VP Global Commercial Development Oncology, (former) AbbVie
Vice President, Mizuho Securities Co., Ltd.
Corporate Development, Renosome Bio
Chairman, BioHouston Inc.
Head of BD, OmniSpirant Therapeutics
Partnerships Manager, Click Therapeutics
CEO & Founder, ANTA Biotech
BDM, Twist
Alliance Management & BD Special Projects, Servier Pharmaceuticals
Head of BD, BRC Therapeutics
Managing Partner, Mission BioCapital
Associate, MVM Healthcare Partners
Director, New Product Planning, EMD Serono
VP Corporate Development, Treadwell Therapeutics
Associate Director BD, TreeFrog Therapeutics
Senior Director Business Development, Fresenius Medical Care, Renal Pharmaceuticals
CEO, Centauri Therapeutics
Partner Strategic Partnerships, Ambrosia Ventures
CEO, Sathgen Therapeutics
BD&Licensing Manager, Biocytogen
Executive Director Alliances & Supply Chain, Zai Lab
Corporate Development, Clasp Therapeutics
Chief Business Officer, Clasp Therapeutics
Therapeutic Strategy Director, Novartis
Chief Development Officer & Chief Business Officer, Precision BioSciences
CFO, ILIAD Biotechnologies
Associate Director Legal Research & Valorization, Sanofi
Corporate Strategy, Servier Pharma
President & CEO, Raya Therapeutic, Inc.
CEO, MetaVia Inc.
Director of Early Pipeline, GCS, Vertex Pharmaceuticals
CBO, Tenza Bio
CBO, Cue Biopharma
Head of international BD and Licensing, Shanghai Pharmaceuticals
CBO, Defand Therapeutics
VP, Head of New Therapeutic Areas BD, EMD Serono
Managing Director, Myeloma Investment Fund
Global Deployment/Integration Lead, Novartis
CEO, Former CEO of TigaTx
Chief Executive Officer, hVIVO
Biomedical Research Integration Office Exec Dir, Novartis
Director, Biomedical Research Integration Office, Novartis Pharmaceuticals
President & CEO, Deka Biosciences Inc
C0-founder & CBO, Deka Biosciences Inc
General Counsel, Deka Biosciences Inc
VP Technical Ops, Deka Biosciences Inc
Sr. Manager BD&Licensing, Biocytogen Boston Corp
Executive Director, Head of Open Innovation, Kyowa Kirin
Business Development & M&A, CorMedix Therapeutics
Associate Director Corporate Development, Ardelyx Inc
CEO, Saros Therapeutics
Counsel, Sanofi
SVP, Investments and Business Development, Ligand
Global Head of Corporate Development, Galderma
Executive Director, BD&L, Merck
Venture Capital, Flusso Capital
Chief Business Officer, Helex Inc.
Director, AI & Digital Health Partnerships, AstraZeneca
Senior Manager, Taiwania Capital
Board Member, Vaccentis AG
VP of Business Development, NodThera
CEO, Founder & Board Member, Clover Key Bioscience
VP, Business Development, Sun Pharma
Head of Corporate Strategy, NB and Integration, Biogen
R&D Alliances Lead, Astellas Pharma
Associate Director Business Development, Qilu Pharmaceuticals
Medical Affairs Technology Lead, Vertex Pharmaceuticals
Head of M&A and Partnering, VP Cell Therapy, Bracco
VP, Business Development, ProMIS Neurosciences
CBO & COO, GlycoMantra
CEO, Canary Cure
AGS, Absci
Chief Business Officer, Stealth food allergy biotech
Program Coordinator, Flagship Pioneering
Investment Committee Chair, London Growth Capital
Head, BD&L Onc & Rad, Bayer Pharma
Partner, Panacea Venture
VP, Associate General Counsel, Intellia Therapeutics, Inc.
VP/Head of Business Development, Menten AI
Director Growth, Bausch and Lomb
General Counsel, Arbor Biotechnologies
Managing Director therapeutics, Outcome Capital
CEO, Tuning Fork Bio
SVP, Florida Private Equity
CSO, Red Arrow Therapeutics
Cofounder and ceo, UmbrAllo Tx
CBO, Expedition Therapeutics
Chairman of the Board, AM Pharma
Managing Director, Sagamore Bioventures
Strategy Associate, CancerFree Biotech
Head of External Innovation, North America, Servier
Manager, Market Research and Competitive Intel, Azurity Pharmaceuticals
Head of Business Development, Model Medicines
Partner, Takeda Ventures
Validation Manager, Drug Packaging and Delivery Sy, West Pharmaceutical Services, Inc.
SVP - Capital Markets, Blaylock Van, LLC
CEO, Ardanza Biopharma AG
CEO, Vaxart
What’s Next in BD&L
Innovation sourcing, disciplined investment strategy, and partnerships that drive real impact..
Key Topics Covered for BD&L
Deal Drivers and Investment Priorities for Big Pharma and VCs
Operating Models for Search and Evaluation to Advance Innovation
IP Due Diligence Issues that can Derail a Deal
Dealmaking Trends and Insights for New Modalities and Technologies
Alternative Deal Constructs and Creative Financing
Negotiating and Evaluating Platform Deals
